For instance, the combined usage of nivolumab (anti-PD-1 mAb) and ipilimumab (anti-CTLA-4 mAb) leads to a 4.74-fold increase in the risk of myocarditis when contrasted with the utilization of nivolumab (anti-PD-1 mAb) as a standalone therapy (122). Here, CTLA4 is linked to myocarditis.